文献速递儿童神经与发育行为

慢波睡眠期持续棘慢波的的治疗实践与结局:多中心协作研究

Treatment Practices and Outcomes in Continuous Spike and Wave during Slow Wave Sleep: A Multicenter Collaboration.
PubMed 文献 · J Pediatr · 2021-01-20

调整基线变量后,苯二氮䓬类(OR 3.32,95%CI 1.57-7.04,P=.002)或类固醇(OR 4.04,95%CI 1.41-11.59,P=.01)的临床改善几率高于其他抗癫痫药物(ASMs),类固醇的脑电图改善几率也高于ASMs(OR 3.36,95%CI 1.09-10.33,P=.03)。

要点

  • 苯二氮䓬类和ASMs是美国CSWS最常用的初始治疗。
  • 苯二氮䓬类和类固醇的临床改善几率优于ASMs。
  • 类固醇的脑电图改善几率优于ASMs,支持更早使用。

核心结论

  • 苯二氮䓬类和ASMs是美国CSWS最常用的初始治疗。
  • 数据提示ASMs疗效不及苯二氮䓬类和类固醇,支持更早使用后两者。

研究设计与样本

  • 回顾性多中心研究,来自美国11家儿科癫痫中心2014至2016年连续收治的CSWS患儿。

主要发现

  • 153次治疗试验中,苯二氮䓬类68次、类固醇25次、ASMs 45次、其他治疗14次。
  • 62%患儿首选苯二氮䓬类,27%首选ASMs作为一线治疗。
  • 调整基线变量后,苯二氮䓬类临床改善OR 3.32(95%CI 1.57-7.04,P=.002),类固醇临床改善OR 4.04(95%CI 1.41-11.59,P=.01),均高于ASMs。
  • 类固醇脑电图改善OR 3.36(95%CI 1.09-10.33,P=.03),高于ASMs。

关键数值与推荐

  • 临床改善定义为治疗医生记录的改善,脑电图改善为脑电图好转。
  • 治疗选择与基线临床变量无关,基线变量亦与结局不相关。

临床怎么用

  • 对于CSWS患儿,可考虑更早使用苯二氮䓬类或类固醇,而非ASMs。
  • 需结合临床改善和脑电图改善综合评估疗效。

局限性

  • 回顾性研究设计。
  • 需多中心前瞻性研究严格评估治疗方案和结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To determine how continuous spike and wave during slow wave sleep (CSWS) is currently managed and to compare the effectiveness of current treatment strategies using a database from 11 pediatric epilepsy centers in the US. STUDY DESIGN: This retrospective study gathered information on baseline clinical characteristics, CSWS etiology, and treatment(s) in consecutive patients seen between 2014 and 2016 at 11 epilepsy referral centers. Treatments were categorized as benzodiazepines, steroids, other antiseizure medications (ASMs), or other therapies. Two measures of treatment response (clinical improvement as noted by the treating physician; and electroencephalography improvement) were compared across therapies, controlling for baseline variables. RESULTS: Eighty-one children underwent 153 treatment trials during the study period (68 trials of benzodiazepines, 25 of steroids, 45 of ASMs, 14 of other therapies). Children most frequently received benzodiazepines (62%) or ASMs (27%) as first line therapy. Treatment choice did not differ based on baseline clinical variables, nor did these variables correlate with outcome. After adjusting for baseline variables, children had a greater odds of clinical improvement with benzodiazepines (OR 3.32, 95%CI 1.57-7.04, P = .002) or steroids (OR 4.04, 95%CI 1.41-11.59, P = .01) than with ASMs and a greater odds of electroencephalography improvement after steroids (OR 3.36, 95% CI 1.09-10.33, P = .03) than after ASMs. CONCLUSIONS: Benzodiazepines and ASMs are the most frequent initial therapy prescribed for CSWS in the US. Our data suggests that ASMs are inferior to benzodiazepines and steroids and support earlier use of these therapies. Multicenter prospective studies that rigorously assess treatment protocols and outcomes are needed.

来源:J Pediatr,查看原文。版权归原作者所有。

引用

  1. Baumer FM, McNamara NA, Fine AL, et al. Treatment Practices and Outcomes in Continuous Spike and Wave during Slow Wave Sleep: A Multicenter Collaboration. J Pediatr. 2021. PMID: 33484700. doi:10.1016/j.jpeds.2021.01.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。